Ampicillin

Ampicillin

SCHEMBL1005406

CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O.CCCc1ncc(C[n+]2ccccc2C)c(N)n1.[Cl-]

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Ampicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.58
RECQL P46063 4/20 0.58
TDP1 Q9NUW8 4/20 0.58
HPGD P15428 3/20 0.58
POLB P06746 2/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
TEK Q02763 1/20 0.58
SLC15A2 Q16348 1/20 0.58
LMNA P02545 6/20 0.57
TSHR P16473 2/20 0.57
USP2 O75604 2/20 0.51
SLC19A2 O60779 1/20 0.51
CASP1 P29466 1/20 0.51
RARB P10826 1/20 0.51
RARG P13631 1/20 0.51
NR1H2 P55055 1/20 0.51
NR1H3 Q13133 1/20 0.51
NR1I3 Q14994 1/20 0.51
CYP3A4 P08684 5/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ampicillin SCHEMBL11233326 0.76 KDM4E (0.88) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL28900655 0.76 KDM4E (0.96) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL13240124 0.76 KDM4E (1.00) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL9528765 0.76 KDM4E (1.00) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL11985596 0.76 KDM4E (1.00) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL24312533 0.76 KDM4E (1.00) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL13014516 0.76 KDM4E (1.00) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL15577318 0.76 KDM4E (1.00) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL22380861 0.76 KDM4E (1.00) KDM4ERECQLTDP1HPGDPOLB
Ampicillin SCHEMBL2282070 0.76 KDM4E (1.00) KDM4ERECQLTDP1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1119345-A4 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GEN MILLS INC (US) 2004-06-16 EP claimed
US-20020044968-A1 High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion GENERAL MILLS, INC. 2002-04-18 US claimed
JP-2002511777-A 2002-04-16 JP claimed
EP-1119345-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. (US) 2001-08-01 EP claimed
WO-2000021504-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. (US) 2000-04-20 WO claimed
EP-0935523-A4 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GEN MILLS INC (US) 1999-12-29 EP claimed
EP-0935523-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GENERAL MILLS, INC. (US) 1999-08-18 EP claimed
WO-1998018610-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES LENGERICH BERNHARD H VAN (US) 1998-05-07 WO claimed
US-20230218874-A1 SWAB DELIVERY SYSTEM ANERGENT PHARMACEUTICALS, INC. (US) 2023-07-13 US disclosed
US-11623075-B2 Buccal swab delivery system ANERGENT PHARMACEUTICALS, INC. (US) 2023-04-11 US disclosed
US-11607392-B2 Encapsulation system for prolonged release of active agents TREND INNOVATIONS (CA) 2023-03-21 US disclosed
US-20200376241-A1 BUCCAL SWAB DELIVERY SYSTEM STATIM PHARMACEUTICALS, INC. (US) 2020-12-03 US disclosed
US-20200297648-A1 ENCAPSULATION SYSTEM FOR PROLONGED RELEASE OF ACTIVE AGENTS TREND INNOVATIONS (CA) 2020-09-24 US disclosed
US-10743604-B2 Articles of manufacture releasing an active ingredient NNTT TECH INC. (CA) 2020-08-18 US disclosed
EP-1065936-A1 ENCAPSULATION OF COMPONENTS INTO EDIBLE PRODUCTS GENERAL MILLS, INC. (US) 2001-01-10 EP disclosed
WO-2000021504-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. (US) 2000-04-20 WO disclosed
EP-0935523-A4 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GEN MILLS INC (US) 1999-12-29 EP disclosed
WO-1999048372-A1 ENCAPSULATION OF COMPONENTS INTO EDIBLE PRODUCTS GENERAL MILLS, INC. (US) 1999-09-30 WO disclosed
EP-0935523-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GENERAL MILLS, INC. (US) 1999-08-18 EP disclosed
WO-1998018610-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES LENGERICH BERNHARD H VAN (US) 1998-05-07 WO disclosed